Helping biotech companies through innovative IT solutions

The cluster-to-cluster project PERMIDES stimulates collaboration between biotech companies and IT companies. Its goal is to develop more innovative, personalized cancer treatments.

 

Oslo Cancer Cluster is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES.

24 May you can benefit from the project by joining the BIOMED INFORMATICS workshop in Oslo. This workshop brings together small and medium sized companies from the biopharma/medtech and IT sectors. (See the sidebar for more info on this event.)

PERMIDES aims to utilize novel IT-solutions to accelerate drug development in biotech companies. Biotechs and the healthcare sector generally lag in using IT in their everyday work.


Can get better at IT

“I know of companies who still manage their clinical trial studies using Excel. This is not a good idea. An Excel sheet may only hold a limited amount of data before it crashes and you lose everything”, says Gupta Udatha.

Udatha is the PERMIDES project leader in Norway. He divides his time between Oslo and Halden, where the NCE Smart Energy Markets-cluster is situated. This cluster is mainly involved in IT. Other clusters participating in the project are from Austria and Germany.


Ambitious goals for next year

Before PERMIDES ends in 2018, it aims to have reached some ambitious goals:

  • 90 innovation projects between IT and biotechs will have received funding through a voucher system
  • 120 IT companies and biotech companies will have benefited from technology transfer activities
  • 75 enterprises will have participated in networking conferences at both regional and European levels
  • 100 companies will have placed their profile in a semantic matchmaking portal: the PERMIDES platform


Find your ideal match

The PERMIDES platform is designed to match IT-companies and biotech companies. As a supplementary service, Gupta Udatha and others involved in PERMIDES are currently busy arranging matchmaking events all over Europe. They try to find the perfect match between IT- and biotech companies interested in collaborating on projects on personalized medical treatment.

Through PERMIDES voucher funding, a biotech company can avail services for up to 60 000 Euros from an IT-company. This gives them a market advantage in digitalizing their processes.

“The health care and biopharma sectors must understand that new IT solutions are the way forward. Tasks which a company may spend weeks and months doing, may easily be done by a few smart IT-solutions, in just few clicks, says Udatha.


Pursuing new EU-programs

PERMIDES is the first EU-project Oslo Cancer Cluster is involved in, but it will not be the last. Oslo Cancer Cluster is actively seeking new EU-projects to apply for.

This year, Oslo Cancer Cluster and Oslo Medtech, another health cluster in Norway, are looking into new EU-projects to apply for together. They have received support from the Norwegian Research Council, that wants more Norwegian institutions and companies to get involved in EU-projects.

“Hopefully, we will have landed ten new EU-project applications by 2019”, says Udatha.

 

What PERMIDES is

  • Stands for Personalized Medicine Innovation through Digital Enterprise Solutions
  • The project is for European small and medium sized enterprises in biotech and IT
  • The aim is to strengthen the competitiveness and foster the innovation potential of personalized medicine as an emerging industry in Europe
  • PERMIDES offers workshops, funding schemes and a matchmaking portal for the participating companies
  • Read more on permides.eu


Clusters involved in PERMIDES
Oslo Cancer Cluster S.A (Norway)
NCE Smart Energy Markets, c/o Smart Innovation Østfold AS (Norway)
Software-Cluster c/o CyberForum e.V. (Germany)
Cluster für Individualisierte ImmunIntervention (Ci3) e.V. (Germany)
Intelligent views GmbH (Germany)
NETSYNO Software GmbH (Germany)
Oncotyrol – Center for Personalized Cancer Medicine GmbH (Austria)
IT-Cluster – Business Upper Austria, OÖ Wirtschaftsagentur GmbH (Austria)


Try our matchmaking platform

Why join the PERMIDES platform? It is where you can find your biopharma-IT match.

 

“Since the launch of PERMIDES in September 2016, we have collected a lot of input from small and medium sized enterprises (SMEs). Several of our members have contributed by sharing their needs and challenges of digitalisation”, says Gupta Udatha, Project Manager for PERMIDES.

PERMIDES kicked off the matchmaking platform on March 15, 2017. During the following two weeks, approximately one hundred SMEs across the globe registered in the platform to find potential partners  for joint biopharma-IT innovation projects in personalised medicine.

There is plenty of room for more companies to benefit from the platform.

Potential project team partners can find each other on the PERMIDES platform. It offers matchmaking of companies from the biopharmaceutical and IT sector, based both on their needs and expertise”, says Udatha.

To be eligible for funding, project teams need to consist of one biopharma SME as the main applicant and at least one IT SME as the service provider.


Funding opportunities

PERMIDES offers different types of vouchers to SMEs allowing them to tackle and solve challenges at specific levels of complexity. Advancing personalised medicine in the digital age requires solutions to issues currently driving the IT and software sector, e.g. Big Data, machine learning, IT security, data protection, and cross-enterprise collaboration.

Each SME can apply for multiple vouchers, but is restricted to the maximum value of each voucher type as detailed at our Open Call for Financial Support. The voucher funding scheme of PERMIDES is aimed at SMEs for developing novel personalised medicine products and solutions.

It is the ambition of PERMIDES to accelerate the digitalisation of biopharmaceutical SMEs in the field of personalised medicine. This is a way of increasing the competitiveness of the participating SMEs.

For more information, visit permides.eu


Do you have questions?
We will be happy to have a meeting with your company and guide you through the PERMIDES funding and collaboration opportunities. Simply contact us if you have questions.

Gupta Udatha
gupta.udatha@oslocancercluster.no
455 34 627

Jutta Heix
jh@oslocancercluster.no
941 63 089

Kick-Off: Call for Proposals for PERMIDES

The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era, to apply for funding up to 60 000 Euros.

 

D.B.R.K Gupta Udatha, project manager for PERMIDES, is very happy to kick off the first call for proposals. He wants to help you succeed in this call for proposal by defining the essentials:

‘In your proposals, you should address the innovation barriers and challenges that you experience in the area of personalised medicine. It should be challenges that somehow can be solved by digitalisation’, says Udatha.

 

Developing novel personalised medicine
The voucher funding scheme of PERMIDES is aimed at small and medium sized enterprises (SMEs) from the biopharmaceutical sector developing novel personalised medicine products and solutions (e.g. biotech/medtech companies, diagnostics companies, CROs, biobank companies, bioinformatic companies).

‘To be eligible for funding, project teams must consist of one biopharma SME as the main applicant or beneficiary. In addition, there must be at least one IT SME as a service provider. Potential team partners in the project can be found via the PERMIDES platform, which offers a matchmaking of companies from the biopharmaceutical and IT sectors’, says Udatha.

 

Get more information:

 

Contact:

Jutta Heix, International Advisor
D.B.R.K Gupta Udatha, Project Manager PERMIDES

 

Update: PERMIDES 1st European Workshop

Oslo Cancer Cluster organized and hosted the ‘1st European Workshop : PERMIDES H2020 Project‘ on 06th December 2016 @ Jónas Einarsson Auditorium, in collaboration with NCE Smart & on behalf of the PERMIDES consortium.

More than 30 delegates from Biopharma, IT and Bioinformatics companies mostly from the Nordic countries actively discussed their innovation barriers and needs along the personalised medicine value chain and digital health revolution. MediSapiens (Finland) and eSmart Systems (Norway) gave stimulating presentations on Digitization of bio-business, Big Data Analytics & Machine Learning aspects. Oslo Cancer Cluster kickstarted the group discussions with an introduction to PERMIDES consortium, the Value Chain Challenges & Topics for Innovation Projects.

During the later half of the workshop, moderated group discussions prioritised the key challenges of biopharma SMEs which can be addressed with the implementation of IT solutions and automatised processes. The workshop thereby provided valuable input for the PERMIDES Innovation Project calls to be launched during the first quarter of the year 2017. In addition, it provided initial matchmaking between participants from the biopharma and IT sector.

Currently we are developing the PERMIDES online platform, where biopharma – IT & bioinformatics SMEs can identify suitable partners to jointly apply for Innovation Vouchers allowing them to address their value chain challenges. For more information, please visit: PERMIDES

 

Given below is the glimpse of the workshop agenda:

agenda

 

For further information and discussions, please contact:

gu-jh

Workshop Update: MyData and Blockchain-based innovation in the Digital Health Sector

Oslo Cancer Cluster hosted a workshop co-organized by Alpha Venturi on “MyData and Blockchain-based innovation in the digital Health sector” on 14 November 2016 @ Jónas Einarsson Auditorium. 

Stakeholders and companies from Norway, Finland, United Kingdom and Estonia have been involved in the brainstorming sessions on several aspects of digital health revolution. The Norwegian Health Directorate, Norwegian Centre for E-Health Research and University in Oulu/Digital Health Revolution from Norway and Finland introduced their respective country perspectives on digital healthcare and progress made relative to MyData.

Multinational biopharmaceutical company Amgen presented their views on the potential gains from such an approach. Alpha Venturi iterated the importance of Blockchain and Distributed Ledger Technologies as a potential game changer for Healthcare among other industries. Two foreign companies, Digi.me from UK and Guardtime from Estonia, have also been invited as external speakers to come and present their respective approach to enable access and sharing of personal health data, one of which based on Blockchain, and the pilots they are implementing respectively in Iceland and Estonia among others.

During this workshop, Alpha Venturi and Oslo Cancer Cluster, moderated the discussions on further perspectives on technologies like Blockchain for Health Care and Personalised Medicine. The first half of the workshop included informative presentations from the delegates, and the later half was focused on brainstorming discussions on potential collaborations.

Alpha Venturi will soon release a report from this workshop that will include short-term and long-term visions, recommendations of the activities and innovation projects in digital health space that can be initiated in Norway in partnership with other Nordic countries. You contact the CEO of Alpha Venturi, Wilfried Pimenta de Miranda at: wilfried@alpha-venturi.com

20161114_103338

Given below is the glimpse of the workshop agenda:

Start Activity Min.
8.45 Arrival of the first participants
9.10 Welcome, presentation of participants and background for the initiative

Oslo Cancer Cluster – Gupta Udatha

Alpha Venturi – Wilfried Pimenta de Miranda

20
9.30 Norway: Overview of the e-health situation and roadmap, examples

Norwegian Health Directorate – Erik Hedlund

10
9.40 Norway: Perspectives on ongoing e-health research and innovation related to MyData

Norwegian Centre for E-Health Research – Gustav Bellika

10
9.50 Finland: Overview of the e-health situation and roadmap, examples

Digital Health Revolution – Maritta Perälä-Heape

20
10.10 The changing data landscape and its impact on biopharma

Amgen- Jonathan Doogan

30
10.40 Pause 10
10.50 A person centric example, Health Iceland Living Lab

Digi.me – Julian Ranger and Andrew Carmody

30
11.20 Q&A 20
11.40 Lunch – Open discussions and networking 60
12.40 Introduction to Blockchain + Use cases in the Health sector

Alpha Venturi – Wilfried Pimenta de Miranda

30
13.10 Healthcare pilot for Estonia

Guardtime – Martin Ruubel

30
13.40 Q&A 20
14.20 Pause 10
14.30 How could a person centric approach be applied to a Norway/Finland healthcare sector 30
15.00 How to make personal data available to individuals 30
15.30 Pause 15
15.45 Building a common vision for the partnership, design principles, initial pilot thoughts 45
16.30 Agreement of next steps; creation of working group to follow up from the day 45
17.15 End & Networking until 17.45 30

For further information and discussions on Oslo Cancer Cluster’s digital health projects, please contact our Project Manager D.B.R.K. Gupta Udatha

D.B.R.K Gupta Udatha

Oslo Cancer Cluster and NCE Smart Energy Markets together with four European clusters in medicine and IT managed to land a prestigious Horizon 2020 EU project. The EU project will use innovative IT solutions to develop personalized cancer treatment. Allocated funds are 45 million NOK, of which 34 million NOK are earmarked for small and medium enterprises in the clusters. The EU project with the sounding name “Personalised Medicine Innovation through Digital Enterprise Solutions: PERMIDES”, will utilize digital tools and novel solutions from the IT sector  to support the development of new cancer treatment. This will be achieved by matching small and medium enterprises from the IT and the biopharma sector for joint innovation projects.

View PERMIDES page